Alterola Biotech INC 10-Q quarterly reports

Alterola Biotech's Q2 2024 financial results reveal a significant increase in operating expenses and net loss as the company continues its strategic shift towards cannabinoid-based pharmaceuticals and prepares for a potential merger.

Alterola Biotech has filed an amended quarterly report to restate its financials for the period ended June 30, 2024, due to an error in consolidating its newly formed subsidiary, Phytanix Bio.

Alterola Biotech, a pharmaceutical company, released its unaudited financial results for the quarter ended June 30, 2024, alongside announcing a business combination agreement with Chain Bridge I.

Alterola Biotech's Q3 2023 report reveals continued operating losses, a significant working capital deficit, and material weaknesses in internal controls, raising concerns about the company's ability to continue as a going concern.

Alterola Biotech's Q3 2023 report reveals increased operating expenses and a larger net loss compared to the same period in 2022, alongside ongoing concerns about the company's ability to continue as a going concern.